Hyperfine Secures FDA Approval for Advanced Optive AI™ Software, Boosting Portable Brain MRI Capabilities

Hyperfine has received clearance from the U.S. Food and Drug Administration (FDA) for its latest imaging software, Optive AI™, marking a major step forward for the company’s portable brain MRI technology. 

This milestone marks the tenth software iteration from Hyperfine and brings substantial improvements to image quality in ultra-low-field MRI scans.

Optive AI™ enhances the full imaging workflow from reducing noise to optimising image acquisition, reconstruction, and post-processing.
 
These updates lead to more consistent, sharper brain images with greater anatomical clarity, benefiting all scan types performed by the system.

Earlier in the year, Hyperfine rolled out the software at selected clinical sites for initial use. Feedback from these locations has been highly favorable, with clinicians noting that the image quality now rivals that of traditional 1.5T MRI machines. 

This leap in quality is particularly valuable in urgent care settings, where fast and accurate bedside imaging can significantly impact patient outcomes.

The launch of Optive AI™ is a key development in Hyperfine’s innovation journey and supports its strategic growth objectives for 2025. 

The software is poised to drive wider adoption of the Swoop® Portable MR Imaging System across hospitals and expand its reach into neurology-focused practices.